Welcome

Bridging the gap between contemporary research and clinical practice, and outline the challenges of anticoagulation for both the treatment of venous thromboembolism (VTE) and the prevention of thromboembolic events in patients with atrial fibrillation is the aim of these modules.

Clinical scenarios will be discussed in detail including clinical challenges illustrated using case histories, focusing on anticoagulant treatment in patients with VTE, with discussion based on the evidence from clinical trials and real world practice from the GARFIELD-VTE registry. A special focus on VTE in cancer patients will be provided with discussion on new clinical trial data and evidence from the FRONTLINE survey and the PERCEIVE registry in patients with newly diagnosed cancer.

New insights on anticoagulation in the prevention of thromboembolic stroke in patients with atrial fibrillation will be provided. International thought leaders will present and lead each module.

Activities

Introduction: The Global Burden of Thrombosis

Thrombosis is the common underlying mechanism in a quarter of global mortality. Cardiovascular diseases are responsible for 45% of all mortality in Europe. Venous thromboembolism (VTE) is an important cause of death in hospitalized patients and treatment of non-fatal symptomatic VTE and related long-term morbidities are associated with a considerable health care costs. VTE carries...

Faculty

Activity Details

  • CreditAmounts:
    • CME: 0.25
    • Other: 0.25
  • Type: Video Webcast Video Activity
  • Expires: May 2, 2020
  • Cost: Free
Learn More
Anticoagulation for VTE – Lessons From Clinical Trials

Selection and duration of appropriate therapy for VTE can be improved in clinical practice. Physicians remain reluctant to prescribe anticoagulant (AC) prophylaxis in a large proportion of the population at risk for thromboembolic stroke.
Risk factors for bleeding in patients receiving thromboprophylaxis must be recognized by the treating physician. The management of VTE...

Faculty

Activity Details

  • CreditAmounts:
    • CME: 0.50
    • Other: 0.50
  • Type: Video Webcast Video Activity
  • Expires: May 2, 2020
  • Cost: Free
Learn More
VTE Management – Evidence From the ‘Real World’

The registry captures real-world data and provides information on adherence to national and international guidelines and identifies treatment deficiencies as well as good practice. The insights of the GARFIELD-VTE and other registries in VTE are important in bridging the gap between contemporary research and clinical practice and also serve to increase awareness of the importance...

Faculty

Activity Details

  • CreditAmounts:
    • CME: 0.50
    • Other: 0.50
  • Type: Video Webcast Video Activity
  • Expires: May 2, 2020
  • Cost: Free
Learn More
The Challenges of Cancer-associated Thrombosis

Important new evidence has recently emerged on the treatment of cancer-associated thrombosis. Patients with cancer carry an increased risk of developing VTE because of tumor- and treatment-mediated hypercoagulability. Clinical risk factors for VTE in cancer include the primary site of cancer, use of systemic therapy (chemotherapy, erythropoiesis-stimulating agents, exogenous...

Faculty

Activity Details

  • CreditAmounts:
    • CME: 0.50
    • Other: 0.50
  • Type: Video Webcast Video Activity
  • Expires: May 2, 2020
  • Cost: Free
Learn More
Preventing Thromboembolic Stroke: State of the Art

Understanding the role of anticoagulant therapy in the prevention of stroke is a prerequisite for initiating a proper treatment regimen. Physicians remain reluctant to prescribe anticoagulant prophylaxis in a large proportion of the population at risk for stroke in part due to misperception of thrombotic risk and concern about bleeding complications, especially among the elderly.

Faculty

Activity Details

  • CreditAmounts:
    • CME: 0.50
    • Other: 0.50
  • Type: Video Webcast Video Activity
  • Expires: May 2, 2020
  • Cost: Free
Learn More
The GARFIELD-AF Registry: How Do These Data Inform Clinical Practice?

International studies such as Global Anticoagulant Registry in the FIELD of atrial fibrillation (GARFIELD-AF) have been important in describing everyday antithrombotic treatment patterns in patients newly diagnosed with non-valvular AF and one or more additional investigator-defined risk factor for stroke. These data have provided valuable insights into the characteristics, risk...

Faculty

Activity Details

  • CreditAmounts:
    • CME: 0.50
    • Other: 0.50
  • Type: Video Webcast Video Activity
  • Expires: May 2, 2020
  • Cost: Free
Learn More
Bleeding and Chronic Anticoagulation

The management of VTE frequently carries significant clinical challenges. Risk factors for bleeding in patients receiving thromboprophylaxis must be recognized by the treating physician. There is a need for improving the perception of strategies in prevention of thromboembolic stroke and concern about bleeding complications, especially among the elderly. The weighing of...

Faculty

Activity Details

  • CreditAmounts:
    • CME: 0.50
    • Other: 0.50
  • Type: Video Webcast Video Activity
  • Expires: May 2, 2020
  • Cost: Free
Learn More
Applying Innovation in Clinical Practice – Interactive Discussion

Selection and duration of appropriate therapy for venous thromboembolism (VTE) can be improved in clinical practice. Physicians remain reluctant to prescribe anticoagulant (AC) prophylaxis in a large proportion of the population at risk for thromboembolic stroke. 

Risk factors for bleeding in patients receiving thromboprophylaxis must be recognized by the treating...

Faculty

Activity Details

  • CreditAmounts:
    • CME: 1.00
    • Other: 1.00
  • Type: Video Webcast Video Activity
  • Expires: May 2, 2020
  • Cost: Free
Learn More
Closing Remarks

VTE is a potentially preventable and treatable condition with the use of anticoagulation therapy. Management aims to reduce mortality and the risks of recurrence and long-term complications. The risk of recurrence is highest in the first 6-12 months after cessation of anticoagulant therapy but a heightened risk persists for at least ten years. Up to 25% of all VTE events occur in...

Faculty

Activity Details

  • CreditAmounts:
    • Other: 0.25
  • Type: Video Webcast Video Activity
  • Expires: May 2, 2020
  • Cost: Free
Learn More